Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

A new advanced form of treatment for one of the deadliest cancers worldwide, pancreatic cancer, may be on its way, research ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting ... Experimental Blood Test for Pancreatic Cancer Undergoing Clinical Development ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...

Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival. The stock fell 32% to $2.64 on Wednesday, losing all its gains ...

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.